Synonyms: ASP015K | JNJ-54781532
peficitinib is an approved drug (Japan (2019))
Compound class:
Synthetic organic
Comment: Peficitinib is an oral Janus kinase inhibitor [5] that was developed for potential anti-inflammatory action in autoimmune diseases including rheumatoid arthritis [6-7], psoriasis and ulcerative colitis [3].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Note that some bioactivity data may be generated using peficitinib hydrobromide (PubChem CID 67998300). We have tagged JAK3 as the primary molecular target for this compound for data metric purposes only, and fully acknowledge its pan-JAK activity. |
Selectivity at enzymes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|